NCT01884246

Brief Summary

Individuals in Appalachian Kentucky are vulnerable to cardiovascular disease (CVD) by virtue of having high rates of multiple CVD risk factors. There is a critical need to develop and test CVD risk reducing interventions that are appropriate and effective in Appalachia. In the absence of such interventions, the dramatic CVD disparities seen in this area will continue to rise. Lifestyle interventions reduce CVD risk by 44%. The investigators and others have demonstrated that lifestyle change is most effective when patients are given the tools to engage in effective self-care, and that interventions individualized to patients' specific needs and barriers are more effective than interventions that are not. The central hypothesis is that to be successful in Appalachia, CVD risk reducing interventions must focus on patient-centered lifestyle change that increase individuals' abilities to engage in self-care, must be culturally appropriate, and must have components that overcome barriers faced by individuals living in Appalachia. The investigators propose a randomized, controlled comparative effectiveness trial with 300 individuals from Appalachian Kentucky who do not have a primary care provider and who are at risk for CVD by virtue of having two or more modifiable CVD risk factors. The investigators will compare (1) a patient-centered, culturally appropriate, self-care CVD risk reduction intervention (HeartHealth) designed to improve multiple CVD risk factors while overcoming barriers to success with (2) referral of patients to a primary care provider for management of their CVD risk factors. The investigators propose the following specific aims to be tested at 4 months and 1 year after baseline. To compare the short and long-term impact of the interventions on: 1\) the risk factor selected by patients (i.e., tobacco use, blood pressure, lipid profile, hemoglobin-A1c (HgA1c) for diabetics, body mass index, waist circumference, depressive symptoms, or physical activity level); 2) all of the CVD risk factors of each patient; 3) quality of life; 4) patient and healthcare provider satisfaction; 5) desirability and adoptability by assessing adherence to recommended CVD risk reduction measures, and retention of recruited individuals. The investigators hypothesize that in comparison to the referral strategy, the multifaceted patient-centered, self-care intervention will engender more favorable outcomes across all measures.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
330

participants targeted

Target at P75+ for not_applicable obesity

Timeline
Completed

Started Aug 2013

Typical duration for not_applicable obesity

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 14, 2013

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 21, 2013

Completed
1 month until next milestone

Study Start

First participant enrolled

August 1, 2013

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2016

Completed
Last Updated

March 10, 2017

Status Verified

March 1, 2017

Enrollment Period

3.4 years

First QC Date

June 14, 2013

Last Update Submit

March 7, 2017

Conditions

Keywords

lifestyle changebehavior changeobesityhypertensionhyperlipidemiaphysical inactivitydepression

Outcome Measures

Primary Outcomes (2)

  • cardiovascular risk factor selected by patient

    Patient selects their own risk reduction goal from the following: smoking, blood pressure, lipid profile, body mass index, hemoglobin-A1c for diabetics, depression, physical activity level, waist circumference

    4 months

  • cardiovascular risk factor selected by patient

    Patient selects their own risk reduction goal from the following: smoking, blood pressure, lipid profile, body mass index, hemoglobin-A1c for diabetics, depression, physical activity level, waist circumference

    12 months

Secondary Outcomes (2)

  • all CVD risk factors of each patient

    4 months

  • all CVD risk factors of each patient

    12 months

Other Outcomes (2)

  • quality of life

    4 months

  • quality of life

    12 months

Study Arms (2)

Self-care CVD risk reduction

EXPERIMENTAL

A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.

Behavioral: Self-care CVD risk reductionOther: Referral to primary care provider for CVD risk management

Referral to primary care provider

ACTIVE COMPARATOR

The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.

Other: Referral to primary care provider for CVD risk management

Interventions

A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.

Also known as: HeartHealth
Self-care CVD risk reduction

The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.

Referral to primary care providerSelf-care CVD risk reduction

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • residents of eastern Appalachian Kentucky
  • do not have a primary care provider
  • at risk for CVD as reflected by having two or more of the following modifiable risk factors
  • clinical diagnosis of hypertension or taking medications diagnosed for hypertension or found to be hypertensive on screening;
  • clinical diagnosis of hyperlipidemia or taking medication for treating abnormal lipid levels, or any lipid abnormality found on screening that indicates hyperlipidemia;
  • diagnosis of type 2 diabetes or HgA1c \> 7% found on screening;
  • overweight or obese (body mass index ≥ 25 kg/m2);
  • waist circumference \> 40 inches in men or \> 35 inches in women;
  • clinical diagnosis of depression, on medications for depression or found to have depressive symptoms (score of \> 9 on the Patient Health Questionnaire-9) by baseline screening;
  • sedentary lifestyle meaning that the individual does not engage in at least 30 minutes of moderate activity for at least 4 days per week

You may not qualify if:

  • known coronary artery disease, cerebrovascular disease, history of acute coronary syndrome or peripheral arterial disease;
  • taking medications (e.g., protease inhibitors) that interfere with lipid metabolism;
  • cognitive impairment that precludes an individual from understanding the consent process, answering questionnaires, or participating in the intervention;
  • chronic drug abuse;
  • end-stage renal or liver or pulmonary disease;
  • current active cancer (i.e., undergoing active treatment for cancer) other than isolated skin cancer treatable by simple excision;
  • gastrointestinal disease that requires special diets (e.g., Crohn's disease; celiac disease)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Kentucky

Lexington, Kentucky, 40535, United States

Location

MeSH Terms

Conditions

ObesityHypertensionHyperlipidemiasDepressionSedentary Behavior

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsVascular DiseasesCardiovascular DiseasesDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesBehavioral SymptomsBehavior

Study Officials

  • Debra K Moser, DNSc, RN

    University of Kentucky

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 14, 2013

First Posted

June 21, 2013

Study Start

August 1, 2013

Primary Completion

December 31, 2016

Study Completion

December 31, 2016

Last Updated

March 10, 2017

Record last verified: 2017-03

Locations